Tackling the Problems Associated with Antimalarial Medicines of Poor Quality by Hamed, Kamal & Stricker, Kirstin
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
Chapter 14
Tackling the Problems Associated with Antimalarial
Medicines of Poor Quality
Kamal Hamed and Kirstin Stricker
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/64671
Provisional chapter
Tackling the Problems Associated with Antimalarial
Medicines of Poor Quality
Kamal Hamed and Kirstin Stricker
Additional information is available at the end of the chapter
Abstract
The  use  of  poor-quality  antimalarials  has  devastating  consequences,  including
increased morbidity, mortality, and drug resistance. Unfortunately, this issue appears
to be widespread, especially in parts of Africa and Asia, jeopardizing the progress and
investments already made in global malaria control in these regions. In developing
countries, inadequate laws and regulatory oversight, along with the lack of human,
technical, and financial resources, do not encourage the manufacture and distribution
of  high-quality  medicines.  The  problem  of  poor-quality  medicines  can  only  be
addressed by a multipronged approach that includes tackling poor regulation and
ineffective/poorly implemented laws at national and international levels. In addition,
pharmaceutical  companies  must  be  responsible  for  ensuring  that  the  quality  of
antimalarials meets the stringent guidelines established by regulatory authorities, for
testing their medicines accordingly and for releasing to market only medicines that pass
these requirements. The chapter also discusses how the implementation of strategies
such  as  the  WHO  Prequalification  Program,  the  African  Medicine  Registration
Harmonization initiative, and the ethical production of medicines by pharmaceutical
companies help to ensure that antimalarial therapies marketed in low-income, malaria-
endemic countries are quality assured.
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1. Introduction
Safe, effective, high-quality, and affordable medicines are essential for the achievement of
positive, equitable health outcomes [1]. They are necessary for the prevention and treatment of
serious public health threats, and for the achievement of the global health goals [2]. However,
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there is growing concern regarding the increasing availability and use of poor-quality medicines,
particularly in developing countries in Africa, Asia, and South America [3–7].
Poor-quality medicines include those that have been falsified (i.e., deliberately and fraudu-
lently mislabeled with respect to identity and/or source) and substandard medicines (i.e.,
products resulting from poor manufacturing with no intent to deceive and usually with
inadequate or too much active pharmaceutical ingredient) [2].
Falsified medicines have resulted in billions of dollars in illegal annual revenues going to
criminals and have caused prolonged, severe illness and deaths. Falsified drugs particularly
affect the most disadvantaged people in poor countries [5].
In particular, the use of substandard antimalarial agents has been reported [3, 4, 7–18]. A World
Health Organization (WHO) survey of antimalarial medicine quality in six countries from sub-
Saharan Africa discovered that nearly 30% of the fully tested samples of medications failed to
comply with internationally recognized quality specifications [8]. Similarly, a review reported
that approximately one third of antimalarial medication samples from sub-Saharan Africa, as
well as from Southeast Asia, failed chemical assay analysis [3].
Factors contributing to poor-quality medicines are numerous [3]. In many developing
countries, for example, first-line artemisinin-based combination therapy (ACT) cannot be
afforded by many patients [4, 5]. Consequently, patients tend to procure cheaper alternatives
that may be falsified or substandard and that may contain subtherapeutic amounts of the active
pharmaceutical ingredients (APIs) or only one of the two active ingredients of the ACT [2,
12]. Thus, the use of such poor-quality antimalarial agents leads to increases in morbidity and
mortality [19]. In addition, subtherapeutic concentrations of drugs in vivo may be contributing
to the selection of resistant parasites [3, 20, 21]. In the face of seemingly ineffective agents,
societies are at risk of losing confidence in antimalarial medicines, their doctors and the
healthcare system, and thus jeopardizing years of global public health success and investment
[2].
In many countries, inadequate laws and regulatory oversight, along with the lack of human,
technical, and financial resources, do not encourage the manufacture and distribution of high-
quality medicines [2, 22]. The WHO has estimated that nearly a third of countries lack the
ability to oversee medicine manufacture, importation, or distribution [23]. With this in mind,
the WHO is playing an important role in establishing quality standards for registration and
quality control of antimalarials by a prequalification program [24]. Initiatives such as the
African Medicine Registration Harmonization (AMRH), in which partners collaborate with
the WHO, have also been started in an attempt to improve quality standards of medicines at
local and regional levels [25]. In addition, pharmaceutical companies must be responsible for
ensuring that the quality of antimalarials meets the stringent guidelines established by
regulatory authorities, for testing their medicines accordingly and for releasing to market only
medicines that pass these requirements [2, 22].
This chapter will discuss the extent and consequences of poor-quality antimalarial medicines.
In addition, the ways in which this issue might be tackled are also discussed, with a focus on
the role of pharmaceutical companies, the WHO, and local and regional initiatives.
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2. Defining poor-quality antimalarials
A variety of definitions have been used to classify the different types of poor-quality medi-
cines [3, 26, 27]. The WHO has attempted to develop a consensus on definitions of poor-quality
medicines, and has outlined two classes of drugs, namely those that are falsified, and those
that are substandard [26].
Falsified medicines have been fraudulently manufactured with fake packaging, and contain
little or no active ingredient (and often other potentially harmful substances) [3, 26]. Falsified
antimalarial tablets and ampoules containing little or no API are a major problem in some
areas [25]. They may be impossible to distinguish from the genuine product and may lead to
under-dosing and high levels of treatment failure. In some extreme cases, the falsified anti-
malarials may contain toxic ingredients [26].
Substandard medicines have been poorly manufactured by a legitimate producer with no
intent to deceive, but they usually have inadequate or excessive amounts of active ingredient(s)
and/or excipients [3, 26]. The WHO also includes degraded drugs within this class [26]. The
degraded drugs were originally of good quality, but become poor quality as a result of
unsuitable or extended storage after manufacturing, or through interaction with inadequate
excipients [3, 26].
3. The growing problem of poor-quality antimalarials
The problem of poor-quality antimalarial agents, particularly those containing artemisinins,
is widespread and varies among countries. There are numerous reports of falsified and
substandard antimalarial agents in particular in Africa and Asia [8–18].
One WHO survey evaluated the quality of selected antimalarials in six countries in sub-
Saharan Africa (Cameroon, Ethiopia, Ghana, Kenya, Nigeria, and United Republic of Tanza-
nia) [8]. Samples were collected and tested for quality by reliable quality control laboratories
according to specifications set up in recognized pharmacopeias. The researchers found that
28.7% of the 267 fully tested samples collected between April and June 2008 failed to comply
with prespecified internationally acceptable quality criteria. A similar proportion of ACTs and
sulfadoxine-pyrimethamine (SP) were subject to quality defects (29% for ACTs and 28% for
SP; Figure 1). Prevailing problems associated with ACTs were related to the content of the APIs
and the presence of impurities. For SP, it was mainly problems related to dissolution. Inter-
estingly, only 4% of the drugs with the WHO prequalification status failed quality analysis,
compared with 60% of drugs not prequalified by the WHO. Therefore, control of the quality
of antimalarial medicines throughout the distribution system, according to proper specifica-
tions, is an important prerequisite for ensuring optimal treatment outcomes [8].
In Southeast Asia, a similar problem with poor-quality medicines has been reported in a review
of published and unpublished data from studies evaluating samples of antimalarials [3]. In
seven Southeast Asian countries, 497 (35%) of 1437 samples failed chemical analysis, 423 (46%)
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of 919 samples failed packaging analysis, and 450 (36%) of 1260 samples were falsified [3]. The
same review also found that, in sub-Saharan Africa (21 countries), 796 (35%) of 2297 samples
failed chemical analysis, 28 (36%) of 77 samples failed packaging analysis, and 79 (20%) of 389
samples were falsified [3].
Figure 1. Proportions of compliant, moderately noncompliant and extremely noncompliant samples of artemisinin-
based combination therapies (ACTs) and sulfadoxine-pyrimethamine (SP) in sub-Saharan Africa [8]. Extreme devia-
tions were defined as a deviation by at least 20% from the declared content to one or more active ingredients, and/or
dissolved percentage of one or more active ingredients less than the pharmacopoeial limit (Q) minus 25%.
The World-Wide Antimalarial Resistance Network (WWARN) has developed a comprehen-
sive, open-access, global database, with a linked Antimalarial Quality Surveyor (an online
visualization tool) in order to more fully understand the evidence relating to poor-quality
antimalarials [15]. A systematic literature search from 1946 to March 2013 identified 251
published antimalarial reports, of which 130 had sufficient information to estimate the
frequency of poor-quality antimalarials [15]. Out of 9348 antimalarials sampled, 30.1% (2813)
failed chemical or packaging quality tests. Of the 2813 failed samples, 39.3% were classified as
falsified, 2.3% as substandard, and 58.3% as poor quality without evidence available to
categorize them as either falsified or substandard. Oral artesunate was the medicine most
commonly reported as falsified (with 61.9% failing). The survey found that 60.6% (63) of the
104 malaria-endemic countries had no publicly available reports on antimalarial drug quality.
Further investigation of the quality of antimalarials is required in the Americas, and in central
and southern African regions, as there have been very few studies conducted in these malar-
ious areas [15].
Studies from individual countries have also reported the existence of poor-quality antimalar-
ials. One recent study used mystery shoppers and overt surveys to identify the quality of
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antimalarials in Cambodia [12]. Of 291 samples tested, 31.3% did not contain an appropriate
amount of the API, i.e., the API content was not within the 85–115% range when measured by
high performance liquid chromatography, and the samples were therefore considered to be of
poor quality.
A recent study of the quality of artemisinin-based antimalarials from Tanzania’s private sector
found that, while none of the 1737 antimalarial samples were falsified, 4.1% were outside the
85–115% artemisinin API range [17]. WHO prequalified drugs (25.7% of the total) were more
likely to be of higher quality, with only 0.5% WHO prequalified drugs being of poor quality,
compared with 5.4% of those not WHO prequalified.
4. Consequences of poor-quality antimalarials
The use of poor-quality antimalarials has serious consequences (see Table 1) [3, 19, 28–36].
Increases in morbidity and mortality
Financial loss for patients, healthcare system, pharmaceutical companies
Loss of public confidence in pharmaceutical brand, medicines, pharmacies, and healthcare providers
Increased drug resistance
Table 1. Consequences of poor-quality antimalarials.
4.1. Morbidity and mortality
Exposure to low-quality antimalarials results in poor treatment outcomes, with increased
morbidity and mortality. The literature contains several case reports of patients placed at risk
or dying as a result of poor-quality antimalarials [28–30]. A study in 39 sub-Saharan African
countries estimated that approximately 122,350 (4%) of the deaths in children aged <5 years
that occurred in 2013 were associated with poor-quality antimalarial agents [19].
The impact of falsified and substandard medicines is likely to extend beyond such increases
in morbidity and mortality. The continued use of poor-quality antimalarials that carry
subtherapeutic levels of active ingredient will most likely lead to drug resistance [26, 31–36].
Partial artemisinin-resistant Plasmodium falciparum malaria has been reported in several Asian
countries in the Greater Mekong Subregion [31–35]. The change in parasite sensitivity is
manifest in the form of delayed parasite clearance, and has been associated with mutations in
the Kelch 13 (K13) propeller region [37]. Indeed, the Greater Mekong Subregion is a major
source from which drug-resistant malaria, including artemisinin-resistant P. falciparum, is
known to emanate [38]. This occurs for multiple reasons, among which the local prevalence of
falsified or substandard artemisinins is an important exacerbatory factor [38]. Based on the
new WHO Global Technical Strategy for malaria 2016–2030, countries in the Greater Mekong
Subregion have established a Strategy for Malaria Elimination in the Greater Mekong (2015–
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2030) in response to the threat of multidrug resistance in this region [36, 39]. The goals of the
strategy are to eliminate P. falciparum malaria by 2025, and all malaria by 2030, in all countries
in the Greater Mekong.
4.2. Resistance
Resistance can be prevented or its outset slowed by the use of combination antimalarials, with
different mechanisms of action [26]. Consequently, the standard of care for uncomplicated
P.falciparum (i.e. move P. from previous page to page 6, line 1 so as not to break P. falciparum (P.
[space] falciparum) malaria is treatment with ACTs [26]. The use of artemisinin monotherapies
in subtherapeutic doses for over 30 years and the availability of substandard artemisinins are
thought to be a major driving force in the selection of the resistant phenotype in these regions
[9, 10, 33]. Moreover, some therapies declared as combinations in effect have been proven to
be artemisinin monotherapies [9]. Resistance to artemisinin compromises the efficacy of the
ACT and adds pressure on the partner drug [26].
Resistance to chloroquine has also been confirmed in Plasmodium vivax in 10 countries [36].
ACTs are now recommended for the treatment of chloroquine-resistant P. vivax, with the
exception of treatment with artesunate and SP, where resistance to the partner drug may
compromise the efficacy of the combination therapy.
4.3. Economic burden
The use of poor-quality antimalarials can have a negative financial impact on patients and their
families [3, 16, 40]. Replacement or additional drugs, repeated courses of poor-quality
antimalarials, repeated consultations at health facilities, and lost work days can all impose an
unwanted economic burden [3, 16, 40], Indeed, recent modeling assuming current incidence
rates of malaria indicates that widespread artemisinin resistance can be expected to lead to
116,000 excess deaths annually [41]. This burden may be particularly severe in some develop-
ing countries, where the majority of the population has to pay for their medicines and the cost
of the medication represents a substantial proportion of the household income [40].
Poor-quality antimalarials also have negative financial consequences for healthcare systems,
pharmaceutical companies, governments and societies, and their use may potentially jeop-
ardize the investments made in the past decades to control and eliminate malaria [3, 16, 40].
The lost productivity and increased healthcare costs associated with the use of poor-quality
antimalarials generally occur in resource-constrained countries that are already dispropor-
tionately bearing the global cost of malaria [36, 40]. These countries generally lack the increased
financial resources needed to inspect, analyze and police the antimalarial supply chain [7].
In particular, the development and spread of resistance to antimalarial medicines has increased
the cost of controlling malaria [36, 40, 41]. A decision-tree model estimated the direct medical
costs for the effective treatment of malaria using ACT in nonresistant areas to be $US114 million
(2013 costs). In comparison, it was estimated that these costs would increase by 28% if ACT
was failing at a rate of 30%, and treatment of severe malaria reverted to quinine [41]. Produc-
tivity losses were estimated to be $US385 million for each year during which failing ACT was
Current Topics in Malaria290
used as first-line therapy [41]. Most of this cost was associated with the lost productivity
associated with excess morbidity after treatment had failed.
The development of resistance to all current antimalarials would necessitate the development
of new, and potentially more expensive, alternatives by pharmaceutical companies, further
adding to the economic burden they incur when a poor-quality alternative is used instead of
their legitimate high-quality product [40].
If clinical trials use poor-quality medicines, not only are resources wasted, but patients may
be harmed [42]. In addition, the erroneous conclusions reached in these trials may inappropri-
ately inform public health policy [42].
5. Tackling the problem of poor-quality antimalarials
A wide variety of issues have contributed to the proliferation of poor-quality medicines in
developing countries (Table 2) [2, 3]. In order for the quality of antimalarials to be assured,
these issues need to be addressed.
Inadequate testing of quality
• Lack of inexpensive surveillance testing systems
• Lack of prequalified laboratories
Poor consumer and healthcare worker knowledge about product authenticity
Inadequate standardization of procedures within quality surveys
Self-prescription of drugs
Availability of products via the Internet
Expensive drugs with large profit margins
Trading in free-trade zones or free ports with minimum regulation
Poor or inadequate national, regional and global legislation, with few legal penalties
Absence of drug regulatory authorities
Unethical practices by manufacturers of antimalarials
Lack of political will and cooperation from stakeholders
Stockouts, thefts, and the erratic supply of antimalarials
Table 2. Factors contributing to the manufacture and distribution of poor-quality antimalarials [2, 3, 16].
It is essential that antimalarial medications be produced according to good manufacturing
practice, contain the correct drug(s) and excipients in appropriate doses, and have bioavaila-
bility that is similar to the reference product; in addition, the drugs must be stored under
appropriate conditions, and be dispensed before their expiry date [26].
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Some of the factors that contribute to the availability of poor-quality medicines can only be
addressed by collaborative action between law enforcement bodies, regulatory authorities,
and customs and excise agencies [26]. Encouragingly, some initiatives and mechanisms are
already in place to help ensure that quality assured antimalarials are available for use in
malaria-endemic countries.
5.1. Detection methods and technology
Tests capable of accurately detecting and classifying poor-quality medicines at the point of
entry into countries and at public and private pharmacies are essential for understanding the
types, names, extent, and amount of poor-quality medicines being dispensed both nationally
and globally [2, 7].
Such tests can be conducted using quick, inexpensive methods in the field with the aim of
examining packaging and detecting drug contents [7]. These tools would also empower those
inspecting the medicines throughout the supply chain [7]. Rather than having to wait for the
samples to be sent to national or international laboratories, results would be available more or
less immediately [7]. Current methods for testing the quality of drugs in the field include visual
packaging inspection, lot number reporting via mobile phones, thin-layer chromatography,
colorimetric tests, and simplified spectroscopic methods [2, 7]. Portable instruments used to
screen for the quality of antimalarial agents include Raman spectrometers and the Global
Pharma Health Fund GPHF-Minilab® [40]. Other simple, technologies for testing the quality
of antimalarials in the field are in development [43, 44].
More accurate methods of testing the quality of medicines involve laboratories that are
equipped for exhaustive chemical analysis [2]. Such investigations can be difficult in develop-
ing countries, given the sophisticated and expensive equipment, the type of reagents, and the
level of technical expertise that are required. For example, Kenya, Tanzania, South Africa, and
Uganda are currently the only countries in Africa with WHO prequalified laboratories for drug
quality testing [19, 45].
5.2. Field reports
Quality surveys can serve as an important source of information about the quality of medicines
available. Data on the quality of antimalarials, if properly collected, interpreted and used, are
essential for the planning of effective interventions [46]. However, reports that have not
employed rigorous scientific techniques will potentially bias results [47]. To ensure consistency
and accuracy, the WHO has recently produced draft guidelines for the conduct of surveys of
quality medicines [46].
5.3. Legislation and regulation
Existing laws in many countries are insufficiently strict to deter the manufacturing and
distribution of poor-quality medicines; where this legislation exists, it may not be implement-
ed [22]. Such absence of legislation prohibiting the manufacture and distribution of poor-
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quality medicines encourages their continued manufacturer, since there is no fear of being
apprehended and prosecuted [2, 22].
Appropriate national medicine regulatory authorities would help to ensure that all pharma-
ceutical products on the market were safe, effective and meet approved quality standards [48].
Such regulation would control registration and postmarketing surveillance (quality monitor-
ing and pharmacovigilance) of medicines, as well as the licensing and inspection of manufac-
turers, importers, exporters, wholesalers, distributors, pharmacies and retail outlets, control
of clinical trials, and control of the promotion (Figure 2) [48]. It has also been suggested that
an international legal convention against poor-quality medicines would address both regula-
tory and criminal international governance challenges [7].
Figure 2. Regulatory system for medicines [48]. GCP, good clinical practices; GDP, good distribution practices; GLP,
good laboratory practices; GMP, good manufacturing practices; GPP, good pharmaceutical practices; GSP, good storage
practices.
However, the WHO has estimated that 30% of member countries lack any capacity to oversee
medicine manufacture, importation, or distribution [23]. At present, only about 20% of member
countries have well-developed medicine regulation at varying levels of development and
operational capacity.
In particular, the lack of global harmonization of drug registration processes is contributing to
the increased availability of poor-quality antimalarials. Regulatory authorities such as the
European Medicines Agency (EMA) and the United States Food and Drug Administration
(FDA) provide guidelines for the registration of new drugs for the pharmaceutical industry.
Such guidelines include steps for assuring drug quality [49, 50]. For example, the FDA
regulates and controls new drugs according to the new drug application process and the
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review and ultimate approval of generic drugs is controlled by regulations for abbreviated
new drug applications.
However, similar rigorous standards are not applied universally, and particularly in sub-
Saharan Africa. Africa currently has more than 50 independent local regulatory health
authority agencies, with different administrative and technical requirements, processes and
timelines for medicine registration and regulatory review, and with variable transparency of
the registration process. A recent WHO assessment in 26 sub-Saharan African countries found
that drug approval regulation was not carried out to the extent required to ensure the quality,
efficacy, and safety of medicines [48]. Few countries in sub-Saharan Africa relied on the
decisions made by other regulators, such as those stringently applied by the EMA or FDA, or
by the WHO through its Prequalification of Medicines Program [48].
5.4. The role of the WHO
Many look to the WHO for leadership in regulating the quality of medicines, especially in light
of its successful implementation of the public health treaty on tobacco control [7].
Due to the association of oral artemisinin monotherapies with the development of resistance,
the WHO urges regulatory authorities in malaria-endemic countries “to take measures to halt
the production and marketing of these oral monotherapies, and promote access to quality-assured
artemisinin-based combination therapies” [51]. The number of countries that allow the marketing
of oral artemisinin monotherapies has dropped markedly since the World Health Assembly
adopted a resolution supporting the ban in 2007. As of November 2015, marketing of artemi-
sinin monotherapies was still allowed by seven countries: Angola, Cape Verde, Colombia,
Gambia, Sao Tome and Principe, Somalia, and Swaziland [51]. However, a continued strength-
ening of pharmaceutical regulation and the enforcement of existing regulations will be
required for the complete withdrawal of oral artemisinin monotherapies from all countries.
In an attempt to standardize the quality of medicines that reach the market, in terms of their
efficacy, safety, and method of manufacture, the WHO are managing the Prequalification of
Medicines Program [24]. This program’s quality evaluation criteria are based on international
pharmaceutical standards and a mix of the best practices applied by the world’s leading
regulatory authorities [52]. Products that meet all of the criteria of the WHO Prequalification
of Medicines Program are considered to be quality assured and are added to a WHO list of
prequalified medicinal products [53]. This list is used by international procurement agencies
and by countries to guide bulk purchasing of medicines. Currently, over 40 of the prequalified
medicinal products on this list are antimalarial agents [53]. This program has validated the
entry of a number of generic products into markets and procurement pools [52]. Such valida-
tion has provided an incentive for other manufacturers of generic products to raise their quality
standards and increase the availability of affordable medicines.
In addition to prequalifying medicines, this program also prequalifies pharmaceutical quality
control laboratories and active pharmaceutical ingredients, as well as advocating for medicines
of guaranteed quality [24].
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5.5. The AMRH initiative
One of the means of improving quality standards is to engage regional networks in developing
countries with larger, more powerful and better resourced organizations such as the WHO.
One example of such a network is the African Medicine Registration Harmonization Initiative
(AMRH) [25, 54]. This program aims to harmonize the registration of medicinal products in
Africa across regional economic communities (RECs) [25, 54]. In Africa, the RECs range in size
from five to more than twenty-five member states—and all have been invited to participate in
the AMRH program.
Partners involved in the AMRH program include the WHO, the New Partnership for Africa’s
Development, the African Union Commission, the Pan-African Parliament, the World Bank,
the Bill and Melinda Gates Foundation, the UK Department for International Development,
and the Clinton Health Access Initiative [25]. The WHO is to provide leadership for the
development of common technical standards, documents, tools, and processes in line with
international standards. The WHO also provides technical assistance for capacity-building and
organizes joint assessment and inspection activities [25].
The first REC to secure funding from the AMRH initiative trust fund was the East African
Community (EAC). The EAC Medicines Registration Harmonization (MRH) project was
formally launched in 2012 in Tanzania and aims to achieve a harmonized medicines registra-
tion process in its member countries (Uganda, Kenya, the United Republic of Tanzania,
Rwanda, and Burundi) based on common documents, processes, and shared information [25].
Given the progress made in the EAC MRH project, the AMRH initiative plans to expand to
other RECs in Africa. It is hoped that five or six groupings will eventually cover the entire
African continent. Continued support by concerned governments and international partners
will be crucial for its success [25].
5.6. The role of pharmaceutical companies
Poor manufacturing and quality-control practices in the production of genuine drugs (either
branded or generic) have considerable impact on the quality of medicines [40]. Pharmaceutical
companies are responsible for ensuring that quality meets the guidelines of stringent health
authorities, for testing their medicines accordingly and for releasing only medicines that pass
these requirements [55]. Chinese and Indian manufacturers are commonly cited as sources of
poor-quality antimalarials, but manufacturers in other countries may also be involved [7, 40].
It is essential that pharmaceutical companies behave ethically at all times and follow relevant
guidelines and codes of conduct provided by regulatory authorities if the quality of medicines
is to be assured.
Reputable pharmaceutical companies must ensure that medicines are under strict surveillance,
and with quality control measures in place at all stages of the drug supply chain. Novartis, for
example, ensures the quality control of medicines in a three-step process that involves
verification, authentication, and pharmaceutical forensic investigations. Verification occurs at
the local level to attest to the genuineness of the packaging materials and the plausibility of
the manufacturing data (batch number, manufacturing, and expiry date). Authentication, done
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in the field, involves analyzing the product (tablets, liquids) with vibrational spectrometers.
In the case of substantiation of falsification of medicines, a pharmaceutical forensic investiga-
tion then occurs, and any substantiated falsification incidents are escalated to the key stake-
holders and national health authorities and the WHO are notified.
Figure 3. Process for review and approval of generic drugs (ANDA) [58]. Source: US Food and Drug Administration
(public domain).
In countries where stringent regulatory authorities exist, pharmaceutical companies develop-
ing new drugs must follow a new drug application process that requires both preclinical and
clinical studies [50]. In contrast, the approval of generic drugs or new formulations of existing
drugs occurs via an abbreviated process that does not require clinical efficacy and safety
studies (Figure 3) [56]. One of the dangers with some generic products is that they may contain
the correct amounts of the drug, but, because of their formulation, they are not adequately
absorbed, resulting in lower efficacy. Consequently, this abbreviated process requires proof
that the generic product (or new formulation of a reference product) and the reference product
have comparable bioavailability. If this is established, the products are said to be bioequivalent
[56, 57].
Different types of evidence may be used to establish bioequivalence for pharmaceutically
equivalent drug products, including in vivo or in vitro testing, or both [56]. If a generic product
or new formulation shows equivalent exposure to the original marketed compound, it is
assumed that its efficacy and safety will also be equivalent [56]. To this end, the WHO
recommended that not only must all antimalarial medicines be manufactured according to
good manufacturing practice and have the correct drug and excipient content, but they must
also be proven to have bioavailability that is comparable to that of the reference listed product
[26].
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An example of a study that was conducted in line with these bioequivalence guidelines
involves the antimalarial artemether-lumefantrine [58]. Because development of this com-
pound adhered to these guidelines, this formulation received the WHO prequalification status
in June 2014 [53]. The novel fixed-dose tablet formulation of the antimalarial artemether-
lumefantrine 80/480 mg was developed in order to reduce the pill burden at each dose and
potentially enhance adherence. It was then tested in a bioequivalence study in healthy
volunteers against four standard tablets of artemether-lumefantrine 20/120 [59]. Bioequiva-
lence between the two formulations was established, with the prespecified criteria for bioe-
quivalence being met. These prespecified criteria were that the 90% confidence intervals for
the geometric mean ratio (novel formulation versus four standard tablets) of the primary
pharmacokinetic endpoints (AUC and Cmax) for artemether and lumefantrine were contained
within the acceptance interval of 0.80–1.25. These outcomes established that the rate and extent
of absorption of both components of the ACT in the novel formulation of artemether-lume-
fantrine are comparable to those in the standard tablets.
6. Conclusion
There is a pressing need to reduce the use of poor-quality antimalarial medicines, especially
in Africa and Asia. The problem is driven by several factors, including a lack of national and
international drug legislation, and inadequate quality assurance by some pharmaceutical
companies. This chapter has reviewed the steps and studies needed to ensure development of
high-quality medicines based on health authority regulations (including WHO prequalifica-
tion). The problem of poor-quality medicines can only be addressed by a multipronged
approach that includes tackling poor regulation and ineffective/poorly implemented laws at
national and international levels. Sustained national and international financing must under-
pin any such future approach. A legal framework or treaty that protects all countries against
poor-quality medicines is also urgently required. Such a framework would facilitate the
production of high-quality antimalarials and protect all countries against those who produce,
distribute, and sell poor-quality products. In addition, pharmaceutical companies must be
responsible for ensuring that the quality of antimalarials meets the stringent guidelines
established by regulatory authorities, for testing their medicines accordingly and for releasing
only medicines that pass these requirements into the market. The harmonization of the
registration process across all nations would help ensure that patients throughout the world
obtain access to high-quality antimalarials.
Surveillance of the quality of antimalarials is an essential component of the global fight against
malaria. The establishment of a highly qualified, well-resourced international organization
that works in collaboration with national medical regulatory bodies, pharmaceutical compa-
nies, and international agencies may help to ensure access to high-quality antimalarials on a
global level. The implementation of strategies such as the WHO Prequalification Program, the
AMRH initiative, and the ethical production of medicines by pharmaceutical companies will
help to ensure that antimalarial therapies marketed in low-income, malaria-endemic countries
are quality assured. Future research must focus on innovative technologies that accurately and
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affordably support the detection of poor-quality medicines at all levels of the supply chain,
including prequalified reference laboratories. It is to be hoped that the implementation of such
a multipronged approach by policy makers and leaders at the international and national levels
will ensure the continued global availability of affordable, high-quality drugs to patients with
malaria.
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